Serum interleukin-6 and interleukin-6 soluble receptor in Alzheimer's disease
Neuroscience LettersPublished 1 March 1998
Pela Angelis, Simon Scharf, Alastair Mander, Frank Vajda, Nicholas Christophidis
Citations84
SJR quartileQ2
SJR score0.77
SNIP0.67
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
There was however, a significant decrease in IL-6sR levels in Alzheimer's patients when compared with controls, suggesting that there is a dysregulation ofIL-6 and its soluble receptor in AD.
Abstract
Serum levels of interleukin-6 (IL-6) and interleukin-6 soluble receptor (IL-6sR) were measured in 41 patients (23 female and 18 male, mean age 72.5 years) with Alzheimer's disease (AD) and in 32 controls (14 women and 18 men, mean age 69.2 years) using enzyme-linked immunosorbent assays (ELISA). Proportions of individuals with detectable serum IL-6 concentrations did not differ significantly between patients and controls. There was however, a significant decrease in IL-6sR levels in Alzheimer's patients when compared with controls. Our results suggest that there is a dysregulation of IL-6 and its soluble receptor in AD.
Keywords
MedicineNeuroscienceBiochemistry, Genetics and Molecular Biology
NeuronThe molecular pathology of Alzheimer's disease
2,700 Citations1991Dennis J. Selkoe
The salient features of the altered biochemistry of AD brain tissue and the possible role of these changes in the pathogenesis of this complex disease are reviewed here.
Proceedings of the National Academy of SciencesInterferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells.
1,656 Citations1987Jack Gauldie, Carl D. Richards +3 more
It is demonstrated that monocyte-derived hepatocyte-stimulating factor and IFN-beta 2 share immunological and functional identity and that IFN -beta 2, also known as B-cell stimulatory factor and hybridoma plasmacytoma growth factor, has the hepatocyte as a major physiologic target and thereby is essential in controlling the hepatic acute phase response.
Proceedings of the National Academy of SciencesInterleukin 6 enhancement of interleukin 3-dependent proliferation of multipotential hemopoietic progenitors.
832 Citations1987Kenji Ikebuchi, GG Wong +4 more
Results indicate that IL-3 and IL-6 act synergistically to support the proliferation of hemopoietic progenitors and that at least part of the effect results from a decrease in the G0 period of the individual stem cells.
Neuroscience LettersInterleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients
788 Citations1995Doris Blum-Degena, Thomas Müller +4 more
The results support the involvement of immunological events in the complex process of neurodegeneration in AD and PD.
The Journal of Experimental MedicineIdentification of the human 26-kD protein, interferon beta 2 (IFN-beta 2), as a B cell hybridoma/plasmacytoma growth factor induced by interleukin 1 and tumor necrosis factor.
679 Citations1987Jo Van Damme, Ghislain Opdenakker +6 more
A factor that promotes the growth of certain B cell hybridomas and of plasmacytomas is shown to be produced by normal human fibroblasts and by a line of human osteosarcoma cells after treatment with IL-1 or TNF.
European Journal of ImmunologyThe soluble interleukin‐6 receptor is generated by shedding
512 Citations1993Jürgen Mülberg, Heidi Schooltink +7 more
The ligand‐binding subunit (gp80) of the human interleukin‐6 receptor (IL‐6R) was transiently expressed in COS‐7 cells and the metabolically labeled protein was shown to be quantitatively released from the membrane within 20 h.
Journal of the American Geriatrics SocietyInterleukin‐6: A Cytokine for Gerontolgists
470 Citations1993William B. Ershler
The biology of this important cytokine is presented and its relevance to gerontology is highlighted and it is proposed that this reflects an age‐associated loss in the normal regulation of gene expression for this molecule.
Immunology TodayIs amyloidogenesis during Alzheimer's disease due to an IL-1-/IL-6-mediated ‘acute phase response’ in the brain?
264 Citations1991Peter Vandenabeele, Walter Fiers
Peter Vandenabeele and Walter Fiers propose possible intracerebral sources of cytokines and acute phase proteins in microglia, astrocytes, neurons and cells of the choroid plexus of Alzheimer's disease.
The Journal of Experimental MedicineT cell growth and differentiation induced by interleukin-HP1/IL-6, the murine hybridoma/plasmacytoma growth factor.
250 Citations1988Catherine Uyttenhove, Pierre G. Coulie +1 more
It is demonstrated that, in the presence of lectins or anti-T cell receptor antibodies, HP1/IL-6 has a growth factor activity equivalent to that of IL-2 for mature thymic and peripheral T cells of both the L3T4+ and Lyt-2+ subsets.
The Journal of BiochemistryPurification and Characterization of Soluble Human IL-6 Receptor Expressed in CHO Cells
151 Citations1990Kiyoshi Yasukawa, Takashi Saito +10 more
A radioisotope immunosorbent assay (RIA) utilizing recombinant sIL-6R was established which could detect IL-6 in a quantity as low as 10 ng/ml and augmented the sensitivity of M1 cells to IL- 6 in growth inhibition assay in a dose-dependent manner.
FEBS LettersThe hepatic interleukin‐6 receptor Down‐regulation of the interleukin‐6 binding subunit (gp80) by its ligand
140 Citations1992Dietlind Zohlnhöfer, Lutz Graeve +4 more
Research in ImmunologyThe participation of interleukin-6 in the pathogenesis of alzheimer's disease
101 Citations1992Jan Bauer, Ursula Ganter +6 more
Clinical and Diagnostic Laboratory ImmunologySerum cytokine levels in patients with Alzheimer's disease
87 Citations1994C C Chao, T A +5 more
It is found that serum TGF-beta levels but not proinflammatory cytokine levels were significantly elevated in patients with AD in comparison with the levels in their healthy spousal controls, which suggests that the diagnostic usefulness of this cytokine for AD is limited.
Neuroscience LettersSerum levels of interleukin-6 are not elevated in patients with Alzheimer's disease
78 Citations1990Cornelia M. van Duijn, Albert Hofman +1 more
There is no evidence for a significant elevation in serum IL- 6 in Alzheimer's disease, and the concentration of IL-6 was not associated with the severity of the dementia or the duration of the disease since first symptoms.
The Journal of Infectious DiseasesCirculating Interleukin-6 Receptor in Patients with Sepsis Syndrome
73 Citations1995Johan Frieling, Marcel van Deuren +5 more
In patients with moderately impaired renal function, sIL-6R levels were not affected, but the concentrations of sTNFRs were significantly higher, and there was a negative correlation between IL-6 and sIL -6R in septic patients.
Neuroscience LettersDecreased interleukin-6 level in the cerebrospinal fluid of patients with Alzheimer-type dementia
70 Citations1995Kiyofumi Yamada, Kazuhiko Kono +11 more
The IL-6 levels in the CSF were not associated with the severity of the dementia or the duration of the disease since the identification of the first symptoms, and were significantly decreased in patients clinically diagnosed with ATD and with vascular dementia.
TransplantationSOLUBLE INTERLEUKIN-6 RECEPTORS IN HEMATOLOGY PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION1
18 Citations1996Amos Toren, Daniela Novick +4 more
Both sIL-6R and IL-6 levels were found to be significantly elevated in patients who developed AGVHD or early relapse following bone marrow transplantation (BMT), and may be used as a tool for assessing engraftment and transplant-related complications following BMT.